Recently, various executives have taken part in insider buying activity for the stocks of Cytori Therapeutics Inc (NASDAQ:CYTX), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Nuance Communications Inc. (NASDAQ:NUAN), and Amgen, Inc. (NASDAQ:AMGN).
Cytori Therapeutics Inc
President and CEO Marc Hedrick bought 10,000 shares worth $3,899 at an average price of $0.39, as reported in the SEC filing yesterday. Following the insider-buying transaction, his stake in Cytori Therapeutics has now grown to $525,711 shares with a value of $205,027.
Click Here to see the performance of Cytori Therapeutics insiders.
Celldex Therapeutics, Inc.
Celldex has been backed by positive insider activity as the company’s Director, Larry Ellberger, acquired a total of 5,000 shares yesterday, taking his total stake to 48,500 shares. The stock purchase was worth $75,000, at an average price of $15.00 per share.
Click Here to see the performance of Celldex Therapeutics insiders.
Nuance Communications Inc.
Director Robert Frankenberg sold 4,162 Nuance Communications shares, valued $32,463, in multiple transactions dated August 18. After completion of the transactions, Frankenberg owns $105,000 shares worth $1,859,550.
Click Here to see the performance of Nuance Communications insiders.
Director Fred Hassan acquired $3,010 Amgen shares (worth $501,545) at a price of $166.63, in two transactions dated August 19. The director now has a total stake of 3,582 shares worth $569,431. According to TipRanks.com, which measures corporate insiders’ success based on their transactions, Fred Hassan has an average return of 2.9% and a 40% success rate. Hassan is ranked #12048 out of 33597 corporate insiders.
Click Here to see the performance of Amgen insiders.